MedTrace Logo

Role of Ultrasound in Diagnosis of Muscle Diseases

NCT04233255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2025-02-25

No results posted yet for this study

Summary

The study aims to provide a timely update on the role of combining clinical and neuromuscular ultrasound assessments in diagnosis and follow-up of various muscle diseases in clinical practice over 12 months period, and correlating US findings with functional scales, biochemical and electrophysiological studies.

Conditions

  • Ultrasound
  • Muscle Disease

Interventions

DEVICE

Neuromuscular Ultrasound (US)

Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler. Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles.

DEVICE

Electrophysiological studies

Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles. using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz.

DIAGNOSTIC_TEST

Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.

measured in U/L using ELISA.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Nageh F. El-Gammal, Doctorate · Assiut University

Eligibility

Min Age
2 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2024-04-04
Completion
2024-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04233255 on ClinicalTrials.gov